Respiratory Therapeutics Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Carcinoma Genetics
Scientists at Seoul National University, Department of Internal Medicine target carcinoma genetics
August 18th, 2008
Researchers detail in 'Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment,' new data in carcinoma. "Mucoepidermoid carcinoma (MEC) of lung is a rare malignancy of lung which originates from minor salivary glands of tracheobronchial tree. EGFR targeted therapy by inhibition of EGFR activation with the specific tyrosine kinase inhibitors (TKIs) has shown meaningful anti-tumor activity in patients with EGFR TK mutation and/or amplification, or in patients with adenocarcinoma," investigators in Korea report. "In the present study, we find that MEC has EGFR mutation in 40% (2 out of 5) of cases, and all mutations are L858R mutation. In addition, we...
Source: Respiratory Therapeutics Week (2008-08-18)
|
